Angiotensin-II receptor antagonist alleviates non-alcoholic fatty liver in KKAy obese mice with type 2 diabetes

Journal of International Medical Research

Volumn 34, Issue 3, 2006, Pages 297-302

  Yu, F ^a,c   Takahashi, T ^a   Moriya, J ^a   Kawaura, K ^a   Yamakawa, J ^a   Kusaka, K ^a   Itoh, T ^a   Sumino, H ^b   Morimoto, S ^a   Kanda, T ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Hospital of China Medical University   (China)

Author keywords

Adiponectin; Angiotensin II receptor antagonist; Candesartan; Diabetes; Non alcoholic fatty liver; Obesity

Indexed keywords

ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; GLUCOSE; LIPID; LIVER PROTEIN; MESSENGER RNA; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; LIPID LIVER LEVEL; LIVER WEIGHT; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

EID: 33745939871     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000603400309     Document Type: Article

References (14)

1. Fong DG, Nehra V, Lindor KD, Buchman AL: Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 2000; 32: 3-10.
2. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW: The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
3. Sheth SG, Gordon FD, Chopra S: Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126: 137-145.
4. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, et al: Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513-1517.
5. Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC: Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003; 285: E906-E916.
6. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I: Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29-33.
7. Pineiro R, Iglesias MJ, Gallego R, Raghay K, Eiras S, Rubio J, et al: Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett 2005; 579: 5163-5169.
8. Xu A, Wang Y, Keshaw H, Xu LY, Lam K, Cooper GJ: The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100.
9. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J: Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001; 10: 321-329.
10. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, et al: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
11. Takahashi T, Zhu SJ, Sumino H, Saegusa S, Nakahashi T, Iwai K, et al: Inhibition of cyclooxygenase-2 enhances myocardial damage in a mouse model of viral myocarditis. Life Sci 2005; 78: 195-204.
12. Yoon D, Lee SH, Park HS, Lee JH, Park JS, Cho KH, et al: Hypoadiponectinemia and insulin resistance are associated with nonalcoholic fatty liver disease. J Korean Med Sci 2005; 20: 421-426.
13. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, et al: Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-1225.
14. Ran J, Hirano T, Adachi M: Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab 2004; 287: E227-E232.